epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-405, Phase III. Recruiting

A rare inherited neuromuscular disorder (genetically confirmed)

TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.

Where EPI-405 stands on September 30th 2026

  • Randomised7of 64 needed
  • Sites open18of 18 planned
  • Median forecast finishJul 2030Deadline Mar 2027
  • Finish41 months lateMedian forecast at the planned sites and rates, against the sponsor's deadline; the Plan tab shows the sites that would close the gap.Open the plan
  • Enrolment47% of planRandomised to date against the count the plan expected by now.Open KPIs
  • SitesToo earlyNo site has been open long enough to judge.Open Sites
  • KRIs0 of 18 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
  • QTLsToo earlyToo few patients yet to judge the study-level limits.Open QTLs

By country

EPI-405 by country
CountrySites openRandomisedBehindWaiting too long for a first patientOver a KRI threshold
United States6 of 62––0 of 6
United Kingdom4 of 40––0 of 4
Spain3 of 32––0 of 3
Poland2 of 20––0 of 2
Turkey1 of 10––0 of 1
India2 of 23––0 of 2